Brief: Onxeo FY net loss widens to 22.7 million euros

Valerio Therapeutics SA

07/03/2017 17:42

March 7 (Reuters) - Onxeo SA  C4X.PA : 
    * FY revenue EUR 4.4 million ($4.65 million) versus EUR 3.5 
million year ago 
    * FY operating loss of EUR 23.2 million versus loss of EUR 
22.4 million year ago 
    * FY net loss EUR 22.7 million versus loss of EUR 19.4 
million year ago 
    * Cash and cash equivalents of EUR 29.2 million at December 
31, 2016 
    * Enrolment for the phase III Livatag study in advanced 
primary liver cancer completed on schedule to deliver 
preliminary results mid-2017 
 
 
Further company coverage:  C4X.PA  
 
($1 = 0.9454 euros) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))